The locomotor hyperactivity selleck inhibitor in mGlu5 receptor KO mice was potentiated by DOM (0.5
mg/kg, subcutaneously (SC)) and attenuated by M100907 (1.0 mg/kg, SC). M100907 (0.1 mg/kg, SC) also blocked the hyperactivity induced by MPEP.
These studies demonstrated that loss of mGlu5 receptor activity either pharmacologically or through gene deletion leads to locomotor hyperactivity in mice. Additionally, the gene deletion of mGlu5 receptors increased the behavioral response to the 5-HT2A agonist DOM, suggesting that mGlu5 receptors either mitigate the behavioral effects of 5-HT2A hallucinogens or that mGlu5 KO mice show an increased sensitivity to 5-HT2A agonists. Taken together, these studies indicate a functional interaction between mGlu5 and 5-HT2A receptors.”
“Despite a general acknowledgment that research in children is necessary and ethical, the evidence base for child-specific treatments is still sparse. SC75741 We investigated children’s biomedical and health services research in the UK in relation to training, infrastructure and activity, research evidence, and visibility. We show that excellent opportunities for career researchers exist through a competitive, national integrated academic training programme, but that the number of
academic paediatricians has decreased by 18% between 2000 and 2011, falling from 11.3% to 5.9% of the consultant workforce. The potential for rapid delivery of studies in children through the National Health Service (NHS) is not being realised: clinical trainees are poorly equipped with core research skills; most newly appointed consultant paediatricians have little or no research experience; less than 5% of contracted consultant time supports research; less than 2.5% of the 2 million children seen in the NHS every year are recruited to studies; and ten of the 20 UK children’s Molecular motor hospitals do not have a clinical research facility. Support through National Institute for Health Research networks is good for studies into drugs, but inconsistent for non-drug research; less than
5% of registered studies involve children and only one children’s biomedical research centre has been allocated funding from 2012. Of the UK annual public and charitable biomedical research expenditure of roughly 2.2 pound billion, about 5% is directed at child health research. The scant evidence base is impeding the development of clinical guidance and policy-less than 20% of the outputs of the National Institute for Health and Clinical Excellence are applicable to children. Paediatric representation on major research boards is weak. Parent and young people’s advocacy is fragmented, and their views are insufficiently heeded by regulatory bodies. The strong UK Government commitment to biomedical research has not been translated fully to research for children.